ADCT analyst estimates

ADC Therapeutics (ADCT) analyst ratings, the average price target and its range, and every firm's latest call.

ADCT analyst ratings and price targets

DateFirmCallTarget
Jun 4, 2026RBC CapitalADC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital$2.00
Jun 4, 2026StephensADC Therapeutics price target lowered to $5 from $8 at Stephens$5.00
Dec 3, 2025RBC CapitalRBC Capital on ADC Therapeutics (ADCT): 'We think the downside is unwarranted and would be buyers on weakness'$5.00
Nov 12, 2025GuggenheimGuggenheim Reiterates Buy Rating on ADC Therapeutics (ADCT)$10.00
May 7, 2024H.C. WainwrightADC Therapeutics (ADCT) PT Lowered to $8 at H.C. Wainwright$8.00
Mar 13, 2024JefferiesADC Therapeutics (ADCT) PT Lowered to $13 at Jefferies$13.00
Nov 14, 2022Morgan StanleyMorgan Stanley Maintains Equal-Weight on ADC Therapeutics, Lowers Price Target to $7$7.00
Sep 9, 2022Morgan StanleyADC Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley$11.00
Aug 22, 2022H.C. WainwrightHC Wainwright & Co. Maintains Buy on ADC Therapeutics, Lowers Price Target to $20$20.00